The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes

Fundamental and Clinical Pharmacology

Volumn 24, Issue 4, 2010, Pages 517-524

  Zwisler, Stine T ^a,b   Enggaard, Thomas P ^a,b   Noehr Jensen, Lene ^a   Mikkelsen, Soeren ^b   Verstuyft, Céline ^c   Becquemont, Laurent ^c   Sindrup, Soeren H ^b   Brosen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

opioid receptor; ABCB1 C3435T G2677T A; OPRM1 A118G; Oxycodone; P glycoprotein; pharmacogenetics

Indexed keywords

OXYCODONE; PLACEBO;

ABCB1 GENE; ADULT; ALLELE; ANTINOCICEPTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLD PRESSOR TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; ELECTROSTIMULATION; FATIGUE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; NAUSEA; NAUSEA AND VOMITING; NERVE STIMULATION; OPRM1 GENE; PAIN; PAIN THRESHOLD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING;

ADULT; ANALGESICS, OPIOID; CROSS-OVER STUDIES; DNA; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; OXYCODONE; P-GLYCOPROTEIN; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; YOUNG ADULT;

EID: 77954398116     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00781.x     Document Type: Article

References (31)

1. Lalovic B., Kharasch E., Hoffer C., Risler L., Liu-Chen L.Y., Shen D.D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. (2006) 5 461 479.
2. Kalso E. Oxycodone. J. Pain Symptom Manage. (2005) 5 (Suppl. S47 S56. (Pubitemid 40720246)
3. Riley J., Eisenberg E., Muller-Schwefe G., Drewes A.M., Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. Curr. Med. Res. Opin. (2008) 1 175 192. (Pubitemid 351160251)
4. Hassan H.E., Myers A.L., Lee I.J., Coop A., Eddington N.D. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J. Pharm. Sci. (2007) 9 2494 2506. (Pubitemid 47477902)
5. Stamer U.M., Stuber F. The pharmacogenetics of analgesia. Expert Opin. Pharmacother. (2007) 14 2235 2245. (Pubitemid 350001587)
6. Lotsch J., Skarke C., Grosch S., Darimont J., Schmidt H., Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics (2002) 1 3 9. (Pubitemid 34112237)
7. Romberg R.R., Olofsen E., Bijl H. et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology (2005) 3 522 530. (Pubitemid 40315140)
8. Skarke C., Darimont J., Schmidt H., Geisslinger G., Lotsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin. Pharmacol. Ther. (2003) 1 107 121. (Pubitemid 36158492)
9. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. (2006) 2 457 473. (Pubitemid 44486412)
10. Ho R.H., Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. (2005) 3 260 277. (Pubitemid 41254111)
11. Cascorbi I., Gerloff T., Johne A. et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. (2001) 3 169 174. (Pubitemid 32225417)
12. Lotsch J., Skarke C., Geisslinger G. Simultaneous screening for three mutations in the ABCB1 gene. Genomics (2003) 5 503 510. (Pubitemid 37239026)
13. Crettol S., Deglon J.J., Besson J. et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. (2006) 6 668 681. (Pubitemid 44920225)
14. Hoffmeyer S., Burk O., von R.O. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. (2000) 7 3473 3478. (Pubitemid 30183327)
15. Kadiev E., Patel V., Rad P. et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin. Drug Metab Toxicol. (2008) 1 77 91. (Pubitemid 351234102)
16. Johne A., Kopke K., Gerloff T. et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. (2002) 5 584 594. (Pubitemid 36237730)
17. Verstuyft C., Schwab M., Schaeffeler E. et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. (2003) 12 809 812. (Pubitemid 36577811)
18. Coller J.K., Barratt D.T., Dahlen K., Loennechen M.H., Somogyi A.A. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther. (2006) 6 682 690. (Pubitemid 44920224)
19. Coulbault L., Beaussier M., Verstuyft C. et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. (2006) 4 316 324.
20. Verstuyft C., Marcellin F., Morand-Joubert L. et al. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS (2005) 18 2127 2131. (Pubitemid 41669001)
21. Kim R.B., Leake B.F., Choo E.F. et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. (2001) 2 189 199. (Pubitemid 32777772)
22. Zwisler S.T., Enggaard T.P., Noehr-Jensen L. et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin. Pharmacol. Toxicol. (2009) 4 335 344.
23. Pedersen R.S., Damkier P., Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin. Pharmacol. Ther. (2005) 6 458 467. (Pubitemid 40824959)
24. Livak K.J. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet. Anal. (1999) 6 143 149. (Pubitemid 29095371)
25. Somogyi A.A., Barratt D.T., Coller J.K. Pharmacogenetics of opioids. Clin. Pharmacol. Ther. (2007) 3 429 444.
26. Lotsch J., Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol. Med. (2005) 2 82 89. (Pubitemid 40193487)
27. Kasai S., Hayashida M., Sora I., Ikeda K. Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch. Pharmacol. (2008) 6 269 281.
28. Bostrom E., Hammarlund-Udenaes M., Simonsson U.S. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology (2008) 3 495 505. (Pubitemid 351304243)
29. Kharasch E.D., Hoffer C., Whittington D., Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin. Pharmacol. Ther. (2003) 6 543 554. (Pubitemid 37521998)
30. Kharasch E.D., Hoffer C., Altuntas T.G., Whittington D. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J. Clin. Pharmacol. (2004) 3 224 233. (Pubitemid 38233819)
31. Kharasch E.D., Hoffer C., Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br. J. Clin. Pharmacol. (2004) 5 600 610. (Pubitemid 38582180)